Skip to main content
Clinical Trials/NCT04368052
NCT04368052
Completed
Not Applicable

Evaluation of The Association Between Cognitive Dysfunction and Brain Cellular Damage During Liver Transplantations

Ege University1 site in 1 country33 target enrollmentFebruary 27, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Brain Damage
Sponsor
Ege University
Enrollment
33
Locations
1
Primary Endpoint
Neuron specific enolase (NSE)
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Neuronal damage caused by neuroinflammation in patients undergoing major surgery is the most determinant factor of postoperative cognitive disfunction (POCD). Neuronal damage can be detected through the measurement of biochemical markers of brain damage. The aim of this study was to evaluate neuronal damage and its association with POCD during liver transplantations. After the approval of the ethics committee and patient consents, preoperative and postoperative cognitive functions of 33 patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels. As a result, there was no statistically significant difference between preoperative and postoperative MMTs. However, there was a statistically significant decrease in postoperative GFAP and a statistically significant increase in NSE compared to preoperative values. The decrease in S100β level was statistically insignificant. In conclusion, neuroprotective approaches in the investigator's anesthesia protocol protect patients from brain damage during liver transplantation and prevent the development of POCD, which was indicated by the insignificant change in MMT scores and S100β level and the significant decrease in GFAP. Since the significant increase in NSE levels during liver transplantations was deemed to might have been associated with causes other than neuronal damage, NSE should not be evaluated as a marker of brain damage in these operations.

Registry
clinicaltrials.gov
Start Date
February 27, 2018
End Date
January 3, 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mustafa Nuri Deniz

Assoc. Prof

Ege University

Eligibility Criteria

Inclusion Criteria

  • Score of 23 or above on the Mini Mental Test (MMT) conducted in the preparation room prior to the operation,
  • No gastrointestinal bleeding in the last 1 month
  • No history of neuroactive drug use
  • Consented for the study.

Exclusion Criteria

  • Hepatic encephalopathy,
  • Neurological disorder
  • Psychiatric disorder,

Outcomes

Primary Outcomes

Neuron specific enolase (NSE)

Time Frame: Throughout the operation

NSE should not be evaluated as a marker of brain damage in liver transplantations.

Secondary Outcomes

  • S-100 beta (S100β), and Glial fibrillary acidic protein (GFAP)(Throughout the operation)

Study Sites (1)

Loading locations...

Similar Trials